"Selinexor–Dexamethasone Combo Induces Objective Responses in Refractory MM"
Selinexor therapy plus dexamethasone was active and induced objective responses in patients with multiple myeloma (MM) who are refractory to current treatment options, according to researchers at the Icahn School of Medicine at Mount Sinai and published in The New England Journal of Medicine. The primary end point of the study was overall response, defined as a partial response or greater, and was assessed by an independent review committee. A secondary end point was clinical benefit, defined as a minimal response or greater. According to lead author Ajai Chari, MD, director of clinical research in the Multiple Myeloma Program at The Tisch Cancer Institute at Mount Sinai, “Selinexor–dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.”
— Ajai Chari, MD, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Mount Sinai Researchers Discover How Melanoma May Spread to the Brain
Apr 30, 2025 View All Press Releases
Mount Sinai Showcases Innovative Cancer Research at 2025 AACR Annual Meeting in Chicago
Apr 24, 2025 View All Press Releases
Mount Sinai Leads Phase 3 Trial in Myelofibrosis Treatment
Mar 19, 2025 View All Press Releases
Mount Sinai Researchers Discover Why Some Colon Cancers Resist Treatment
Feb 12, 2025 View All Press Releases
Breakthrough Treatment for Liver Cancer Shows Big Promise in Global Study
Jan 09, 2025 View All Press Releases
Mount Sinai Researchers Create AI Tool to Democratize Access to Cancer Immunotherapy
Jan 06, 2025 View All Press Releases